News

Endpoints News21h
FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill
In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...
Endpoints News21h
Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...
Endpoints News22h
Am­gen in­vests $900M to ex­pand Ohio bio­man­u­fac­tur­ing
Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.
Endpoints News20h
Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...
Endpoints News23h
RFK Jr. touts CMS pro­gram test­ing new ways to pay for sick­le cell dis­ease treat­ment
HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...
Endpoints News23h
Com­pound­ing phar­ma­cies dealt a blow in fight over end of semaglu­tide short­age
A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...
Endpoints News6h
Earn­ings sea­son is up­on us; Makary on rare dis­ease; Start­up is first to in­ject CRISPR in the brain; and more
Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.